专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110020384A1 THERAPEUTIC TB VACCINE 失效
标题翻译：治疗TB疫苗
公开(公告)号：US20110020384A1
公开(公告)日：2011-01-27
申请号：US12785053
申请日：2010-05-21
申请人： PETER ANDERSEN , Ida Rosenkrands , Anette Stryhn
发明人： PETER ANDERSEN , Ida Rosenkrands , Anette Stryhn
IPC分类号： A61K39/04 , A61P31/06
CPC分类号： C07K14/35 , A61K39/04 , A61K2039/55572 , A61K2300/00
摘要： Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing tuberculosis.
摘要翻译：提供包含在分枝杆菌感染潜伏期期间表达的多肽的治疗性疫苗，以及多相疫苗以及治疗和预防结核病的方法。

2. 发明申请

US20030036638A1 Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product 失效
标题翻译：用于大规模生产Gc球蛋白的纯化方法，由此产生的Gc-球蛋白，使用G球蛋白和Gc-球蛋白药用产品
公开(公告)号：US20030036638A1
公开(公告)日：2003-02-20
申请号：US10217787
申请日：2002-08-13
申请人： Statens Serum Institute
发明人： Charlotte Svaerke Joergensen , Inga Laursen , Gunnar Houen
IPC分类号： C07K016/00
CPC分类号： A61K38/1709 , C07K14/47
摘要： A purification process for large-scale production of Gc-globulin is described. The source of Gc-globulin is preferably a crude plasma fraction but can be any solution, suspension or supernatant containing Gc-globulin, e.g., a milk product, colostrum or a fermentation broth. The Gc-globulin can be plasma-derived or produced by a genetic modified organism. The process includes two key elements: purification by series of ion exchange chromatography steps, and performing at least two virus-reduction steps. A diagnostic method to measure the free Gc-globulin in a patient blood sample, a use of Gc-globulin in medicine and the preparation of a Gc-globulin medicinal product is also provided. The product can be used in therapy for patients with circulatory disorders and complications, i.e., where it is contemplated that said patients would benefit from the administration of Gc-globulin.
摘要翻译：描述了用于大规模生产Gc球蛋白的纯化方法。 Gc-球蛋白的来源优选是粗血浆级分，但可以是含有Gc-球蛋白的任何溶液，悬浮液或上清液，例如乳制品，初乳或发酵液。 Gc-球蛋白可以是血浆衍生的或由遗传修饰的生物体产生的。该方法包括两个关键要素：通过一系列离子交换色谱步骤纯化，并进行至少两个病毒还原步骤。还提供了测量患者血液样品中游离Gc-球蛋白的诊断方法，Gc-球蛋白在药物中的用途以及Gc-球蛋白药用产品的制备。该产品可用于治疗患有循环系统疾病和并发症的患者，即预期所述患者可从Gc-球蛋白的给药中受益。

3. 发明申请

US20080153116A1 DIAGNOSTIC BLOOD TEST USING ADSORPTION ON FILTER PAPER 有权
标题翻译：使用过滤纸吸附的诊断血液检测
公开(公告)号：US20080153116A1
公开(公告)日：2008-06-26
申请号：US11948264
申请日：2007-11-30
申请人： Gunnar HOUEN , David Hougaard , Kristin Skogstrand , Charlotte Svaerke Jorgensen
发明人： Gunnar HOUEN , David Hougaard , Kristin Skogstrand , Charlotte Svaerke Jorgensen
IPC分类号： G01N33/53 , G01N33/68 , G01N33/92 , G01N33/563
CPC分类号： G01N33/521 , G01N33/48 , G01N33/66 , G01N33/68 , G01N33/92 , Y10T436/143333
摘要： A diagnostic test and method is provided comprising mixing blood or another biological fluid sample with a test compound and spotting the blood on filter paper for subsequent analysis of the effect of the test compound on the blood. The biological fluid can be a cerebrospinal fluid, a peritoneal fluid, a cyst fluid, an amniotic fluid, a lavage fluid, a saliva, a cell extract or a tissue extract. The compound is chosen among an amino acid, a peptide, a protein, a carbohydrate, an oligosaccharide, a polysaccharide, a glycoprotein, a lipid, a lipoprotein, a glycosaminoglycan, a hormone, a steroid, a vitamin, a low molecular weight synthetic or natural compound which influences the blood to cause an alteration of its composition, e.g., a toxin, allergen, autoantigen, bacterial protein or polysaccharide, viral protein, fungal protein or polysaccharide, parasitic protein or polysaccharide, bacterial lipopolysaccharide or any other compound relevant to diseases.
摘要翻译：提供了一种诊断测试和方法，包括将血液或另一种生物流体样品与测试化合物混合，并在滤纸上点样，随后分析测试化合物对血液的影响。生物流体可以是脑脊液，腹膜液，囊液，羊水，灌洗液，唾液，细胞提取物或组织提取物。该化合物选自氨基酸，肽，蛋白质，碳水化合物，寡糖，多糖，糖蛋白，脂质，脂蛋白，糖胺聚糖，激素，类固醇，维生素，低分子量合成物或影响血液以引起其组成变化的天然化合物，例如毒素，变应原，自身抗原，细菌蛋白或多糖，病毒蛋白，真菌蛋白或多糖，寄生蛋白或多糖，细菌脂多糖或与疾病

4. 发明申请

US20080008724A1 Expanding the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails 失效
标题翻译：通过用作为蛋白质片段或肽鸡尾酒递送的抗原进行疫苗接种来扩展T细胞谱，以包括亚显性表位
公开(公告)号：US20080008724A1
公开(公告)日：2008-01-10
申请号：US11823402
申请日：2007-06-27
申请人： Claus Aagaard , Jes Dietrich , Peter Andersen
发明人： Claus Aagaard , Jes Dietrich , Peter Andersen
IPC分类号： A61K39/00 , A61K39/002 , A61K39/04 , A61K39/12 , A61P43/00 , C12P21/04
CPC分类号： A61K39/00 , A61K39/04 , A61K2039/55511 , A61K2039/5555 , Y02A50/412
摘要： A convenient way of inducing a broad recognition of dominant and subdominant responses to epitopes of any given antigen of importance for prophylaxis or treatment of a chronic disease is provided. The method involves by immunizing with pools of overlapping fragments (synthetic peptides, e.g., 10-30 mers with 2-20 aa overlap) of the desired antigen in appropriate adjuvants. The T cell repertoire is primed to include not only the immunodominant epitope recognized when the intact molecule is used for immunization and induced by the chronic infection itself, but induce a much broader and balanced response to a number of the subdominant epitopes as well. The vaccination with peptide mix induces a T-cell response that includes response to subdominant epitopes is important for protection against chronic disease that on their own induces a response focused only on immunodominant epitopes. The major advantage of the present invention is that it requires no prior knowledge of the precise localisation and identity of the subdominant epitopes and their recognition in a human population, but expands the T-cell repertoire and thereby the total number of epitopes recognized by specific T cells primed by vaccination from a few immunodominant epitopes to a multiple of epitopes.
摘要翻译：提供了一种方便的方法来诱导对预防或治疗慢性疾病具有重要意义的任何给定抗原的表位的显性和亚显性反应的广泛认识。该方法涉及通过用合适的佐剂中的所需抗原的重叠片段（合成肽，例如，10-20个重叠的2-20个重叠）的池进行免疫。引导T细胞谱不仅包括当完整分子用于免疫并由慢性感染本身诱导时识别的免疫显性表位，而且还诱导对多个亚显性表位的更广泛和平衡的响应。用肽混合物接种诱导T细胞应答，其包括对次优势表位的应答对于针对仅针对免疫显性表位的反应的慢性疾病的保护是重要的。本发明的主要优点在于，它不需要在人群中亚显性表位的精确定位和识别的先验知识，而且扩展了T细胞谱，从而扩展了特定T识别的表位总数通过从几个免疫显性表位接种到多个表位而引发的细胞。

5. 发明申请

US20100015171A1 VACCINES COMPRISING TB 10.4 审中-公开
标题翻译：包含结核病的疫苗10.4
公开(公告)号：US20100015171A1
公开(公告)日：2010-01-21
申请号：US12500881
申请日：2009-07-10
申请人： Jes Dietrich , Claus Aagaard , Peter Andersen
发明人： Jes Dietrich , Claus Aagaard , Peter Andersen
IPC分类号： A61K39/04 , A61K38/16 , C07K14/35 , A61P37/02
CPC分类号： A61K39/04 , A61K2039/545 , A61K2039/55516 , A61K2039/55561
摘要： Vaccination with the combination of Ag85B-TB10.4 and IC31® adjuvant generated a high amount of polyfunctional CD4+T cells expressing high levels of IFN-γ, TNF-α, and IL-2. This in turn led to significant protection against infection with M. tuberculosis in the mouse aerosol challenge model of tuberculosis. Both the immunogenicity of the vaccine and its ability to protect against TB infection was highly dependent on the antigen dose. Thus, whereas the standard antigen dose of 5 μg, as well as 15 μg, did not induce significant protection against M. tuberculosis, reducing the dose to 0.5 μg increased both the immunogenicity of the vaccine as well as its protective efficacy to a level comparable to that observed in BCG vaccinated mice. Thus, the IC31® adjuvant, with the specified antigen dose, can induce a strong protective Th1 response against M. tuberculosis.
摘要翻译：使用Ag85B-TB10.4和IC31（R）佐剂的组合进行疫苗接种产生大量表达高水平IFN-γ，TNF-α和IL-2的多功能CD4 + T细胞。这反过来又导致了结核病小鼠气溶胶攻击模型中结核分枝杆菌感染的重大保护。疫苗的免疫原性及其抗TB感染的能力都高度依赖于抗原剂量。因此，尽管5杯以及15杯的标准抗原剂量没有诱导对结核分枝杆菌的显着保护，但将剂量降低至0.5杯可将疫苗的免疫原性以及其保护功效提高到可比水平到BCG接种的小鼠中观察到的。因此，具有特定抗原剂量的IC31R佐剂可以诱导针对结核分枝杆菌的强烈的保护性Th1应答。

6. 发明申请

US20030065039A1 Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones 审中-公开
标题翻译：生物活性的1,3-双 - 芳族 - 丙-2-烯-1-酮，1,3-双 - 芳族 - 丙-1-酮和1,3-双 - 芳基 - 丙-2-炔-1-酮 -那些
公开(公告)号：US20030065039A1
公开(公告)日：2003-04-03
申请号：US10062208
申请日：2002-01-31
申请人： Statens Serum Institute
发明人： Arsalan Kharazmi , Soren Brogger Christensen , Simon Feldbaek Nielsen
IPC分类号： A61K031/12
CPC分类号： C07C255/40 , A61K31/12 , A61K31/136 , A61K31/277 , C07C45/00 , C07C45/41 , C07C45/455 , C07C45/67 , C07C45/673 , C07C45/74 , C07C49/813 , C07C49/84 , C07C205/45 , C07C217/22 , C07C217/36 , C07C225/16 , C07C225/22 , C07C233/33 , Y02A50/409 , C07C47/565 , C07C47/575
摘要： The invention relates to the use of 1,3-bis-aromatic-prop-2-en-1-ones (chalcones), 1,3-bis-aromatic-propan-1-ones (dihydrochalcones), and 1,3-bis-aromatic-prop-2-yn-1-ones for the preparation of pharmaceutical compositions for the treatment or prophylaxis of a number of serious diseases including i) conditions relating to harmful effects of inflammatory cytokines, ii) conditions involving infection by Helicobacter species, iii) conditions involving infection by viruses, iv) neoplastic disorders, and v) conditions caused by microorganisms or parasites. The invention also relates to novel chalcones and dihydrochalcones (especially alkoxy substituted variants) having advantageous substitution patterns with respect to their effect as drug substances, and to methods of preparing them, as well as to pharmaceutical compositions comprising the novel chalcones. Moreover, the present invention relates to a method for the isolation of Leishmania fumarate reductase, QSAR methodologies for selecting potent compounds for the above-mentioned purposes.
摘要翻译：本发明涉及1,3-双芳族 - 丙-2-烯-1-酮（查耳酮），1,3-双芳族 - 丙-1-酮（二氢查耳酮）和1,3-二 - 用于制备用于治疗或预防许多严重疾病的药物组合物的双芳族 - 丙-2-炔-1-酮，包括i）与炎性细胞因子的有害作用有关的病症，ii）涉及幽门螺杆菌感染的病症，iii）涉及病毒感染的病症，iv）肿瘤性疾病，以及v）由微生物或寄生虫引起的病症。本发明还涉及具有相对于其作为药物物质的效果的有利取代模式的新型查耳酮和二氢查耳酮（特别是烷氧基取代的变体）及其制备方法，以及包含新颖的查尔酮的药物组合物。此外，本发明涉及用于分离富马酸利什曼原虫还原酶的方法，用于选择上述目的的有效化合物的QSAR方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式